Zoetis Inc. (ZTS)
Health Care4 articles
Price chart
Why is ZTS moving today?
+1.2%ZTS is +1.2% today, inside the ordinary range for a session (under 3%). No stories about it reached the feed in the last 24 hours.
What this does not prove. A story on the same day is evidence of timing, not of cause: it explains a move only if it accounts for the size and the direction, and most single-stock moves carry a sector or index component too. Nothing here is a forecast.
Source: Yahoo Finance - quote as of 2 days ago
Zoetis Inc. (ZTS) overview
Zoetis is the world’s largest animal-health company.
ZTS is a member of the S&P 500. It sits in the Health Care sector. That sector covers pharmaceutical, biotech, device and managed-care companies.
Zoetis Inc. trades on the NYSE under the ticker symbol ZTS. The most recent market data puts the share price at about $79.38. That is up 1.22% on the session. At that price the company is worth roughly $32.80B.
Over the past 52 weeks, ZTS has traded between $68.77 and $148.30. Shares change hands at a trailing price-to-earnings (P/E) ratio of about 13.1. The P/E ratio sets the share price against a year of earnings. A higher number means the market is paying more for each dollar the company earns. ZTS also pays a dividend. It yields around 2.67% at the current price.
Key statistics
Source: Yahoo Finance - quote as of 2 days ago
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
Why investors watch ZTS
ZTS is one of the larger names in the Health Care sector, so investors follow it closely. It tends to move with the rest of the sector. This page sums up each ZTS story as it breaks, and tags it bullish, bearish or neutral.
What moves ZTS
- Earnings. ZTS reports results four times a year. A surprise against the estimate tends to move the stock that day.
- Analyst calls. Upgrades, downgrades and new price targets change what the market expects from ZTS.
- Sector news. Health Care stocks often move together, so a rival's news can move ZTS too.
Market Mood
Latest ZTS news
Zoetis (ZTS) Reports Flat Q2 2026 Revenue at $2.5 Billion
Zoetis Inc. (NYSE: ZTS) reported fiscal Q2 2026 revenue of $2.5 billion, reflecting flat performance and a 1% decline on an organic operational basis. The decline was primarily driven by pressures within the U.S. companion-animal market, which saw a 7% revenue drop and 11% decline in companion-animal product sales. Conversely, livestock revenue grew 12%, bolstered by a 23% increase in the U.S. Livestock segment. The company is looking to restore growth through a pipeline of over 12 potential blockbuster candidates and the recent acquisition of VitalRADS for expanded diagnostics. This matters for investors as it highlights Zoetis's resilience and potential for future growth despite current market challenges.
Read More: Zoetis (ZTS) Reports Flat Q2 2026 Revenue at $2.5 Billion
Zoetis (ZTS) Director Michael McCallister Buys $233,273 in Shares
Michael McCallister, a director at Zoetis (ZTS), purchased shares totaling $233,273. This stock buy may signal McCallister's confidence in the company’s future prospects. Such insider buying can influence market perceptions and potentially affect stock prices as investors interpret it as positive sentiment regarding the company's trajectory. Monitoring these insider trades can provide insights into the firm's growth potential and market strategy.
Read More: Zoetis (ZTS) Director Michael McCallister Buys $233,273 in Shares
Zoetis (ZTS) Releases DEF 14A Filing for April 30 Meeting
Zoetis Inc (ZTS) filed its DEF 14A with the SEC for the upcoming shareholder meeting on April 30. This filing includes details on executive compensation and proposed changes to governance. Such disclosures are vital for investors assessing company management and expected performance. The filing may influence shareholder voting on key issues affecting the business.
Read More: Zoetis (ZTS) Releases DEF 14A Filing for April 30 Meeting
Zoetis (ZTS) Q3 2024 Revenue Grows 14% Operationally
In Q3 2024, Zoetis (ZTS) reported a 14% operational revenue growth, driven by a 15% increase in the U.S. and a 13% increase internationally. Adjusted net income saw a 15% operational rise, with key franchises, including the companion animal portfolio, also growing by 15%. The osteoarthritis pain franchise, consisting of Librela and Solensia, delivered a significant 97% operational revenue increase globally. This consistent growth reflects demand for their diverse and science-driven portfolio, positioned to address customer needs effectively.
Read More: Zoetis (ZTS) Q3 2024 Revenue Grows 14% OperationallyMore Health Care stocks
Frequently asked questions
Is Zoetis Inc. in the S&P 500?
Yes. Zoetis Inc. trades as ZTS and is a member of the S&P 500. The index lists it in the Health Care sector.
What sector is ZTS in?
ZTS sits in the Health Care sector of the S&P 500.
Where can I find the latest ZTS news?
Right here. This page collects recent ZTS news and market analysis. Every story gets an AI summary and a bullish, bearish or neutral tag.
What is Zoetis Inc.'s stock price?
ZTS last traded at about $79.38. Prices move all through the session, so this is the latest quote rather than a live one.
What is Zoetis Inc.'s market cap?
ZTS is worth roughly $32.80B. Market cap is the share price times the number of shares outstanding.
What is ZTS's P/E ratio?
ZTS trades at a trailing P/E ratio of about 13.1. The ratio compares the share price with earnings per share over the past year.